## REVIEW

## **Open Access**

## Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy

Check for updates

Ajaz A. Bhat<sup>1†</sup>, Sabah Nisar<sup>1†</sup>, Selma Maacha<sup>2†</sup>, Tatiana Correa Carneiro-Lobo<sup>3†</sup>, Sabah Akhtar<sup>4†</sup>, Kodappully Sivaraman Siveen<sup>4†</sup>, Nissar A. Wani<sup>5†</sup>, Arshi Rizwan<sup>6</sup>, Puneet Bagga<sup>7</sup>, Mayank Singh<sup>8</sup>, Ravinder Reddy<sup>9</sup>, Shahab Uddin<sup>4</sup>, Jean-Charles Grivel<sup>2</sup>, Gyan Chand<sup>10</sup>, Michael P. Frenneaux<sup>11</sup>, Mushtaq A. Siddiqi<sup>12</sup>, Davide Bedognetti<sup>3,13,14</sup>, Wael El-Rifai<sup>15</sup>, Muzafar A. Macha<sup>12\*</sup> and Mohammad Haris<sup>1,16\*</sup>

## Abstract

Esophageal cancer (EC) is a disease often marked by aggressive growth and poor prognosis. Lack of targeted therapies, resistance to chemoradiation therapy, and distant metastases among patients with advanced disease account for the high mortality rate. The tumor microenvironment (TME) contains several cell types, including fibroblasts, immune cells, adipocytes, stromal proteins, and growth factors, which play a significant role in supporting the growth and aggressive behavior of cancer cells. The complex and dynamic interactions of the secreted cytokines, chemokines, growth factors, and their receptors mediate chronic inflammation and immunosuppressive TME favoring tumor progression, metastasis, and decreased response to therapy. The molecular changes in the TME are used as biological markers for diagnosis, prognosis, and response to treatment in patients. This review highlighted the novel insights into the understanding and functional impact of deregulated cytokines and chemokines in imparting aggressive EC, stressing the nature and therapeutic consequences of the cytokine-chemokine network. We also discuss cytokine-chemokine oncogenic potential by contributing to the Epithelial-Mesenchymal Transition (EMT), angiogenesis, immunosuppression, metastatic niche, and therapeutic resistance development. In addition, it discusses the wide range of changes and intracellular signaling pathways that occur in the TME. Overall, this is a relatively unexplored field that could provide crucial insights into tumor immunology and encourage the effective application of modulatory cytokine-chemokine therapy.

**Keywords:** Esophageal cancer, Cytokines, Chemokines, Inflammation, Tumor microenvironment, Epithelial-Mesenchymal transition, Drug targets, Immune evasion

\* Correspondence: muzafar.aiiims@gmail.com; mharis@sidra.org

 $^{\dagger}\text{Ajaz}$  A. Bhat, Sabah Nisar and Selma Maacha contributed equally to the first authorship.

<sup>†</sup>Tatiana Correa Carneiro-Lobo, Sabah Akhtar, Kodappully Sivaraman Siveen and Nissar A. Wani contributed equally to the second authorship.

<sup>12</sup>Watson–Crick Centre for Molecular Medicine, Islamic University of Science

and Technology, Awantipora, Jammu & Kashmir, India

<sup>1</sup>Functional and Molecular Imaging Laboratory, Cancer Research Department, Sidra Medicine, Doha, Qatar

Full list of author information is available at the end of the article



<sup>©</sup> The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.